Maria del Pilar Acosta-Lara
Pulmonary Disease · Dothan, ALNPI 1679717342
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,905 of the $12,795 with a category attached, or 69.6%. Genentech USA, Inc. accounts for 80.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $10,271 and has fallen 90.9% since, to $932 in 2025.
Across 55 payments — averaging $232.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$10K
- Boehringer Ingelheim$2K
- United Therapeutics Corporation$229
- Sanofi$165
- AstraZeneca$156
- GSK$117
- plus $331 from 7 others
What the payments were for
- Consulting fees$1,30010%
- Speaking & faculty fees$8,90570%
- Travel & lodging$1,1109%
- Food & beverage$1,48012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $10,271 |
| Boehringer Ingelheim | 7 | $1,527 |
| United Therapeutics Corporation | 6 | $229 |
| Sanofi | 5 | $165 |
| AstraZeneca | 7 | $156 |
| GSK | 6 | $117 |
| Regeneron Healthcare Solutions, Inc. | 4 | $86 |
| Amgen | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Verona Pharma, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $22 |
| Mylan Specialty L.p. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$1,416
How this compares
$12,795 in reported general payments places this provider in the 80th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 99 | $1,218,497 |
| Pirfenidone | 63 | $172,964 |
| RemicadeInfliximab | 13 | $80,886 |
| Dupixent PenDupilumab | 14 | $49,885 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $38,590 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $35,897 |
| Mycophenolate Mofetil | 69 | $7,785 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,686 |
| Mycophenolic AcidMycophenolate Sodium | 12 | $5,714 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $4,091 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,804 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,930 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $2,141 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,078 |
| Azathioprine | 30 | $1,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $1,527 | $1,218,49799 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $117 | $81,172149 claims |
| AstraZenecaSymbicort | $156 | $2,07811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Dothan
- Marvin SextonDothan$18K
- Walter DotyDothan$12K
- Alan PurvisDothan$9K
- William SaliskiMontgomery$257K
- Emily RehbergSylacauga$166K
- Tejaswini KulkarniBirmingham$134K
- Adrian DivittorioMobile$100K
- Luther CorleyHuntsville$86K
- Peter LutzMobile$63K
- Mohammad AzamTuscaloosa$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.